Published in Genes Immun on August 01, 2002
CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis (2003) 1.29
Chemokine receptor 5 △32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis (2010) 1.03
Immunogenetic factors associated with severe respiratory illness caused by zoonotic H1N1 and H5N1 influenza viruses. Clin Dev Immunol (2011) 0.96
The influence of human leukocyte antigen class I alleles and their population frequencies on human immunodeficiency virus type 1 control among African Americans. Hum Immunol (2011) 0.93
Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis. PLoS One (2012) 0.81
A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med (1989) 10.98
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med (1984) 6.11
Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med (1977) 5.86
PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol (1997) 5.76
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health (1996) 5.45
Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
Self-reported antiretroviral therapy in injection drug users. JAMA (1998) 4.75
Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med (1989) 4.72
Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. Arch Intern Med (2001) 4.68
Transmission of the human immunodeficiency virus. N Engl J Med (1987) 4.17
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr (1999) 4.15
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol (1991) 3.99
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA (1992) 3.81
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med (1983) 3.67
Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men. Am J Public Health (1988) 3.66
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS (2001) 3.56
Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med (2000) 3.15
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA (1992) 3.07
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol (2000) 2.97
Reliability of self-reported sexual behavior risk factors for HIV infection in homosexual men. Public Health Rep (1988) 2.93
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Voluntary testing for human immunodeficiency virus (HIV) in a prison population with a high prevalence of HIV. Am J Epidemiol (1994) 2.81
Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity. N Engl J Med (1987) 2.81
Factors associated with adolescent initiation of injection drug use. Public Health Rep (2001) 2.73
Genetic analysis of IDDM: the GAW5 multiplex family dataset. Genet Epidemiol (1989) 2.73
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 2.68
Correlates of HIV infection among young adult short-term injection drug users. AIDS (2000) 2.63
Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns. Arch Intern Med (1985) 2.62
Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS (2000) 2.61
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Using social network analysis to study patterns of drug use among urban drug users at high risk for HIV/AIDS. Drug Alcohol Depend (1995) 2.51
HIV infection in women in the United States: status at the Millennium. JAMA (2001) 2.51
Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis (2001) 2.51
Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis (2001) 2.49
Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol (1997) 2.48
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Phylogenetic comparative analysis and the secondary structure of ribonuclease P RNA--a review. Gene (1989) 2.45
Nonadherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic. AIDS Care (2005) 2.42
Knowledge of HIV antibody status and decisions to continue or terminate pregnancy among intravenous drug users. JAMA (1989) 2.41
Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis. N Engl J Med (1986) 2.40
Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med (1992) 2.36
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol (1997) 2.32
Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA (1992) 2.32
Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. Am J Epidemiol (2003) 2.32
The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30
People and places: behavioral settings and personal network characteristics as correlates of needle sharing. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.26
Vitamin A deficiency and wasting as predictors of mortality in human immunodeficiency virus-infected injection drug users. J Infect Dis (1995) 2.25
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
Survival differences in patients with AIDS. J Acquir Immune Defic Syndr (1991) 2.23
Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team. J Acquir Immune Defic Syndr (2000) 2.22
Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health (2001) 2.21
Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS (1999) 2.20
Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction. Cell (2001) 2.20
High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA (1992) 2.19
Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr (2001) 2.13
Hierarchical pattern of mucosal candida infections in HIV-seropositive women. Am J Med (1990) 2.11
Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. Arch Intern Med (1995) 2.08
Explaining racial disparities in incidence of and survival from out-of-hospital cardiac arrest. Am J Epidemiol (2007) 2.07
The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE Study. Am J Community Psychol (1996) 2.07
Streptococcus bovis septicemia and carcinoma of the colon. Ann Intern Med (1979) 2.06
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach. J Acquir Immune Defic Syndr (1991) 2.04
Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care (2003) 2.04
Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction (1993) 2.01
Transmission of HIV-1 within a statewide prison system. AIDS (1988) 2.00
The discipline of teams. Harv Bus Rev (1993) 1.97
Occupational risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infections among funeral service practitioners in Maryland. Infect Control Hosp Epidemiol (1995) 1.95
Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Ann Intern Med (1993) 1.92
Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and among asymptomatic controls in Boston. Ann Intern Med (1985) 1.89
Human T-lymphotropic virus type III in high-risk, antibody-negative homosexual men. Ann Intern Med (1986) 1.88
Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev (1994) 1.87
Scaphoid malunion. J Hand Surg Am (1989) 1.87
T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis (1997) 1.85
Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect (2001) 1.85
HIV testing, counseling, and prophylaxis after sexual assault. JAMA (1994) 1.83
Compliance with universal precautions among health care workers at three regional hospitals. Am J Infect Control (1995) 1.83
Screening immigrants and international travelers for the human immunodeficiency virus. N Engl J Med (1990) 1.81
Characterization of a lysine-specific active transport system in Rickettsia prowazeki. J Bacteriol (1977) 1.80
Prevalence of diabetes in Mexican Americans. Relationship to percent of gene pool derived from native American sources. Diabetes (1984) 1.80